61results about How to "Novel chemical structure" patented technology

It is intended to provide novel amine compounds which are efficacious against diseases such as infection with HIV virus, rheumatism and cancer metastasis. Namely, amine compounds represented by the following general formula (1):

In a typical case, A1 and A2 represent each an optionally substituted monocyclic or polycyclic aromatic heterocycle; W represents cyclic C3-10 alkylene, an optionally substituted monocyclic or polycyclic aromatic heterocycle, a monocyclic or polycyclic aromatic ring or a partly saturated polycyclic aromatic ring; X represents O, CH2, C(═O) or NR11; and D is a group represented by the following general formula (4) or (6).

In the formula (6), Q represents a single bond, S, O or NR12; and Y is a group represented by the following general formula (7).

z represents an optionally substituted monocyclic or polycyclic aromatic ring. In the formula (6), B represents NR25R26. In the above formulae, R1 to R26 each represents hydrogen, alkyl, alkenyl or alkynyl.

The invention relates to a bridged dipyrene-3,4,6,7-12, 13, 15, 16-octcarboxylic acid tetraimide compound containing sulphur atoms or selenium atoms and a preparation method thereof. 1,6, 7,12-tetrahalogenated pyrene-3,4-9,10-tetracarboxylic acid diimide compound or 1,9,10,18-tetrahalogenated dipyrene-3,4,6,7-12, 13, 15, 16-octcarboxylic acid tetraimide compound, sodium sulfide or sodium selenide, a catalyst, an amino acid ligand and inorganic base are mixed; then an organic solvent is added; the reaction is carried out under the protection of inert gas; the product is dissolved in the solvent, is washed in sodium chloride aqueous solution, and is dried and filtrated; then the solvent is distilled to dryness; and the bridged dipyrene-3,4,6,7-12, 13, 15, 16-octcarboxylic acid tetraimide compound containing sulphur atoms or selenium atoms in the lateral position showed by formula(I) or (II) is obtained through column chromatography separation. The yield after purification is 10 to 40 percent.

A polyglycolized derivative of thymopeptide-5, which can be used to prepaer the medicines for preventing and treating rheumatoid arthritis, allergic dermatisis, tumor, viral infection, and the diseases associated with immune deficiency and hypoimmunofunction, is disclosed. Said derivative features that the polyglycol, polyglycol modified amino acid, cysteine, maleamido glycol, vinyl glycol, or iodoacetylglycol is introduced or coupled to the N or C terminal of thymopeptide-5.

The invention relates to a vancomycin derivative as shown in the formula (I) and a stereisomer, pharmaceutically acceptable salts, a preparation method of the vancomycin derivative and its application in treating and/or preventing diseases or symptoms related to gram negative bacterial infections.

The invention discloses polyaryletherketone containing an indole group and a preparation method of polyaryletherketone. The polyaryletherketone is shown in formula (I). The preparation method includes the following steps: under the protection of nitrogen, adding 4-hydroxyindole, a keto-group-containing difluoro monomer, a bisphenol monomer, a salt-forming agent, a solvent and methylbenzene in a reactor; stirring the mixture evenly, and conducting heating to increase the temperature to 130-140 DEG C for reaction for 3-4 hours; distilling off methylbenzene, and then increasing the temperature to 160-190 DEG C for continuous reaction for 4-6 hours; cooling the materials obtained after the reaction to room temperature, and pouring the materials in deionized water for sedimentation; conducting suction filtration to obtain a solid product, conducting extraction with methyl alcohol, and drying the solid product obtained by suction filtration to obtain polyaryletherketone containing the indole group. The polyaryletherketone containing the indole group is good in thermal stability, relatively high in glass transition temperature, good in solubility and unique in optical property, and can be used in battery diaphragms, optoelectronic devices, electrode materials, inertial confinement fusion film targets and other fields. Please see the formula in the specification.

The invention discloses substituted xanthine compounds, a preparation method and applications thereof, and specifically relates to compounds represented by the formula (I), stereo isomers and pharmaceutically acceptable salts thereof, wherein the R1 and R2 are defined in the description. The invention also relates to a pharmaceutical composition containing the compounds, an application of the pharmaceutical composition in preparation of drugs for treating diseases or symptoms caused by high activity of DPP-IV or overexpression of DPP-IV, and a method using the pharmaceutical composition to treat related diseases. The provided compounds can effectively inhibit the activity of DPP-IV.

A red light fluorescent material adapted for being excited by a first light to emit a red light is provided. The red light fluorescent material has the chemical formula (1) presented below,

A₂Eu(MO₄)(PO₄)  (1),

• • in which A represents Li, Na, K, Rb, Cs, or Ag, and M represents Mo, W, or a combination thereof (Mo_xW_(1-x)). The red light fluorescent material can provide a red light with high luminance and good color purity. Moreover, since the composition of the red light fluorescent material includes oxides, the red light fluorescent material has high chemical stability and long lifetime.

A kind of antineoplastic antibiotic compound, chinikornycin A and B, for suppressing the cells of lung cancer, breast cancer, melanoma, renal cancer and uterine cancer is prepared from Streptomyces sp. through fermenting and chromatography by silica gel column.

The invention belongs to the technical field of medicinal chemical industry, and discloses an oxygen-substituted phenylimidazole XOR/URAT1 dual inhibitor, preparation and applications thereof, whereinthe oxygen-substituted phenylimidazole XOR/URAT1 dual inhibitor has a structure represented by a formula (A), R1 represents C1-C7 alkyl, R2 is -COOH or -COOC2H5, and R3 is -H or -CH3. According to the present invention, the oxygen-substituted phenylimidazole XOR/URAT1 dual inhibitor has the chemical structure different from the known XOR/URAT1 dual inhibitor, has excellent effects on both key targets of XOR and URAT1 related to gout, and can be used for preparing anti-hyperuricemia or anti-gout drugs.

The invention relates to a micromolecular reversible BTK inhibitor for treating rheumatoid arthritis, and specifically provides a compound. The compound is the compound as shown in a formula I, or a stereisomer, a geometrical isomer and a tautomer thereof, nitric oxide, aquo-complex, a solvate, a metabolite and pharmaceutically acceptable salts and prodrugs. The inventor finds that polysubstitutedquinolone compound or derivate thereof as shown in formula I can be used as the BTK inhibitor and is high in activity during treating rheumatoid arthritis.

The invention discloses bisbenzylisoquinoline betaine with anti-tumor activity and a preparation method thereof. The compound has the following structural general formula shown in the specification. The preparation method comprises the steps of taking bisbenzylisoquinoline compounds as raw materials, dissolving into a certain solvent, adding a catalyst and a reactant Y, mixing, performing reaction for 0.1-72 hours at -20 DEG C to 300 DEG C, performing hydrolysis and neutralization reaction on the materials after reaction, and then separating and purifying to obtain an objective product. According to the preparation method disclosed by the invention, the prepared bisbenzylisoquinoline betaine has a relatively good inhibiting effect on proliferation of the human liver cancer cell strain HepG2 and leukemia K562 cells, and can be used for preparing anti-tumor medicaments.

The invention belongs to the technical field of medicine and relates to a triazolopyridine compound and a preparation method and application thereof, in particular to a triazolopyridine compound having the structure of general formula I and its stereoisomers and pharmaceutically acceptable salts, wherein R1, R2, R3 and R4 are described as in the claims and the description. All the triazolopyridinecompound, its stereoisomers and pharmaceutically acceptable salts, and a composition containing the triazolopyridine compound can evidently inhibit interaction of PD-1/PD-L1 protein/protein, are suitable for treating the various diseases, such as cancers and viral infections, and therefore, are applicable to the preparation of drugs to prevent and/or treat diseases associated with PD-1/PD-L1 signal pathway.

The invention relates to a triterpenoid compound as shown below and a preparation method and use thereof. It is shown through several in vitro immunosuppressive activity tests that the compound has anobvious effect on inhibiting lymphocyte proliferation in mice and are expected to be used in the preparation of immunosuppressive drugs. The triterpenoid compound and the preparation method and use thereof can provide lead compounds for the development of new drugs for the treatment of autoimmune diseases and organ transplant rejection.

The invention relates to a benzophenone bisamide bridged diquaternary ammonium salt type light-induced synergistic antibacterial agent and a preparation method thereof. The preparation method comprises the following steps: taking 3,3',4,4'-benzophenonetetracarboxylic dianhydride and an N,N-dimethyl fatty amine compound as raw materials, and performing a condensation reaction to obtain a benzophenonetetracarboxylic diamide compound intermediate; performing a quaternization reaction to obtain the benzophenone bisamide bridged diquaternary ammonium salt type light-induced synergistic antibacterial agent. The antibacterial agent involved in the invention has synergistic efficient antibacterial properties of a light-induced quaternary ammonium salt unit and a benzophenone bisamide unit, and has the advantages of mild reaction conditions, simple preparation process and the like at the same time.